When cost stops being the barrier: The new chapter of Ozempic injection in India | India News
Most evenings at the diabetes clinic, the conversation eventually comes back to the same word: cost. Not calorie, not carb counting, consumption. For many patients, drugs like Ozempic occupy an uneasy place between medical progress and affordability. Doctors spoke of their benefits with measured optimism; The patients listened, did the math, and quietly returned to the old drugs, strict diets, and long walks.That equation may just change.With the patent for semaglutide (Ozempic) expiring on March 20, Indian pharmaceutical majors viz. Sun PharmaZydus Lifesciences, Dr Reddy’s and Natco Pharma are gearing up to roll out more affordable versions of the once exclusive injectables. What was until now a premium therapy could soon become a mainstream prescription, potentially reshaping India’s fast-growing anti-obesity and diabetes market.
Photo: DD
But cheaper medicine does more than expand access, it also signals a change in behavior.Over the years, treatment plans for obesity and type 2 diabetes in India have leaned heavily on lifestyle changes: disciplined diets, exercise regimens, and increased pharmaceutical support when needed. Semaglutide, celebrated worldwide for its dual effects on blood sugar and weight loss, has launched a powerful new liver. Yet its price has ensured that it is a last resort for many, rather than an option they choose first.As generics enter the scene, doctors may rethink when to prescribe it. Patients who once delayed therapy may start earlier. Weight management clinics may see a surge. And the uneasy balance between lifestyle and medicine, between personal discipline and pharmacological support, can tilt in unexpected ways.The question now is not just whether semaglutide will be cheaper. How India deals with weight, health and responsibility can afford to quietly reshape boundaries.
How does Ozempic work?
To understand why semaglutide has generated so much excitement and controversy, it helps to start with what it actually does inside the body.After we eat, our gut releases hormones called incretins. These chemical messengers tell the pancreas to make insulin, helping to move sugar out of the bloodstream and into the cells where it is needed. They also signal the liver to slow down its sugar production and give the brain a simple message: You’ve had enough.Ozempic works by amplifying that natural system.
.
Its active ingredient mimics a hormone known as glucagon-like peptide-1 (GLP-1), which the body produces after a meal. In people with type 2 diabetes, this response is often blunted. Semaglutide acts to strengthen it. When blood sugar levels rise, it prompts the body to release insulin, removing excess glucose from the liver and slowing the rate at which food leaves the stomach. The combined effect is stable blood sugar levels and improved HbA1c readings, which essentially help with long-term glucose control.But the drug’s effects don’t stop at sugar.GLP-1 also acts on the hunger centers of the brain. It signals satiety, that subtle feeling of fullness that prompts one to put down the fork. By creating a more stable and long-lasting version of this hormone, semaglutide amplifies that feeling. For people with obesity, that change can mean a lot. The constant mental battle around food calms down. Weight loss is less about constant moderation and biology working in their favor.
Low prices, wide access — and a market on the rise
More players are lining up to join the fray in the coming months and price pressure is expected to increase with each new entrant. Until now, India’s weight-loss medicine segment has largely been the playground of high-priced innovator brands, accessible only to a select few. That exclusivity may not last much longer.Industry observers estimate the current weight-loss market at around Rs 1,400 crore and they believe it could double within a year if prices soften and supply expands. Appetite, both medical and consumer, clearly exists.The momentum isn’t just limited to obesity medicine. The broader anti-diabetic therapy market grew more than 15% in January, driven largely by new, premium treatments, according to data from research firm Pharmarack. Among them is Eli Lilly’s Mounjaro, which generated Rs 112 crore in sales — a sign that patients and doctors are willing to embrace innovation, even at higher price points.“The patent expiry is going to have a lot of impact on the market. The expiry is going to be on the 20th and by the 21st we have got a report that 5 different semaglutides are going to be launched,” said Raman Nath of Nath Drugs.What is changing now is the equation between demand and capacity. If generics bring costs down meaningfully, these drugs could move from specialty, urban prescriptions to more mainstream therapy. And with that change, the conversation about weight and diabetes management in India may become less about who can afford cutting-edge care — and more about how widely it can be used.“Doctors prescribe such drugs based on the economic background of the patients. If they find that the patient is healthy, they will prescribe drugs like Ozempic, otherwise they will prescribe cheaper alternatives,” added Raman.
Beyond weight loss: The body image question
Beyond clinics and balance sheets, another, quieter debate is unfolding, a mirror, about the meaning of self-worth and acceptance.In recent months, the conversation around GLP-1 drugs like Ozempic has moved beyond the blood sugar and BMI charts. In social media panels and televised debates, some commentators have suggested that if weight can be medically reduced, movements focused on body acceptance may begin to lose weight. The implication is subtle but powerful: if body size is seen as easily modifiable with an injection, there is a risk that living in a larger body is made a choice rather than a complex mix of biology, environment and circumstances.Over the years, the body positive movement has argued for dignity and inclusion, regardless of size. This pushes back against the idea that value is measured in kilograms. But public perceptions and attitudes may change as drugs like semaglutide become more visible and potentially more affordable. If being thin becomes medically achievable, will social tolerance shrink?
These drugs help control appetite and blood sugar; They don’t outright shame, stigmatize, or internalize years of criticism. Research has long shown that body size and body image are closely related. It’s not surprising, then, that some people may hope that losing weight will quiet a harsh inner voice or soften the way the world responds to them.Yet access remains unequal, outcomes vary, and no injection can fully untangle the emotional layers tied to diet and appearance. As semaglutide becomes more mainstream, India may find itself navigating not just a medical shift, but a cultural one, balancing the promise of better health with the need to preserve compassion, dignity and choice for bodies of all sizes.“In this country, two types of drugs are sold the most. One is to be fair and one is to be slim. Ozempic helps in the slimming part. People rarely want to change their lifestyle. To be thin you have to make a lot of changes and be aware of how you live, what you eat. Ozempic makes it so easy that ten people have lost weight by taking it.”
Risk of abuse
Originally designed to treat type 2 diabetes, these drugs have gained a second identity as powerful tools for rapid weight loss. For many patients, the results are dramatic, even life-changing, reductions that old diets, pills, and fitness fads rarely deliver. No wonder they are being described as game changers.But as their popularity grows, so do questions.Most GLP-1 drugs are taken as a once-weekly injection, self-administered into the arm, thigh, or abdomen. Treatment usually starts with a low dose that is gradually increased. Within a few weeks, many users notice a change: thirst dulls, portions shrink, constant mental chatter around food softens. For some, the scales begin to tip for the first time in years.
AI generated images
Yet doctors insist that these drugs are not magic, and not casual lifestyle items. Weight often returns within a year of stopping the drug, as the body’s biological drive to regain lost weight reasserts itself. Without regular exercise, especially strength training, patients can lose muscle along with fat, a concern in a country where diets are often high in carbohydrates and low in protein.“It is indicated for weight loss therapy but should be taken only under medical guidance. There is always a possibility of misuse unless the sale is restricted,” said Dr Arun Mundhara, senior consultant physician, Civil Lines, Sant Parmananda Hospital.There are other limits, too. Not everyone responds to GLP-1 therapy, and many people hit a plateau after losing about 15% of their body weight. Side effects are usually manageable, nausea, bloating, diarrhea, but rare complications such as gallstones or pancreatitis can occur. Prolonged, unsupervised use carries its own risks.Dr. Mundhara also emphasized that the use of semaglutide will increase manifold once cheaper generics are available.
